APTOのチャート
APTOの企業情報
| symbol | APTO |
|---|---|
| 会社名 | Aptose Biosciences Inc （アポト―ス・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アプトス・バイオサイエンセス（Aptose Biosciences Inc）（旧名：Lorus Therapeutics Inc.）は、生命科学会社。同社は、安全性プロファイルのある効果的抗癌治療法の発見・研究・開発を行う。また、前臨床から完成第I相臨床試験に至るまで様々な段階の製品で、多様的抗がん製品パイプラインを確立する。 アポト―ス・バイオサイエンシズはカナダのバイオ医薬品企業。主に腫瘍への対応標的治療薬の発見と開発に従事する。同社はさまざまな臨床段階の医薬品と市場性のある抗がん医薬品を手掛け、主要パイプライン「LOR-253」は、急性骨髄性白血病と骨髄異形成症候群を含む高度な血液悪性腫瘍向けのものである。本社はオンタリオ州。 Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada. |
| 本社所在地 | 251 Consumers Road Suite 1105 Toronto Ontario M2J 4R3 CAN |
| 代表者氏名 | William Glenn Rice ウィリアム・グレン・ライス |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 647-479-9828 |
| 設立年月日 | 31656 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 20人 |
| url | www.aptose.com |
| nasdaq_url | https://www.nasdaq.com/symbol/apto |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.14960 |
| 終値（lastsale） | 2.1 |
| 時価総額（marketcap） | 72781121.7 |
| 時価総額 | 時価総額（百万ドル） 68.17641 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 49.71241 |
| 当期純利益 | 当期純利益（百万ドル） -23.04202 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aptose Biosciences Inc revenues was not reported. Net loss increased from $5.7M to $17.1M. Higher net loss reflects Research and development - Balancing val increase from $0K to $5M (expense) Program cost increase from $1.9M to $4.5M (expense) Stock-based compensation increase from $386K to $2.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.54. |
APTOのテクニカル分析
APTOのニュース
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020 2020/07/21 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly…
Aptose Announces Proposed Public Offering of Common Shares 2020/07/15 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced…
Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp? 2020/06/29 13:31:00 PR Newswire
NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Aptose to launch early-stage CG-806 study in acute myeloid leukemia (NASDAQ:APTO) 2020/06/29 11:38:37 Seeking Alpha
Aptose Biosciences (NASDAQ:APTO) is up 7% premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase
Aptose Biosciences : 2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas | MarketScreener 2020/06/22 15:12:05 MarketScreener
CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas … | June 22, 2020
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020 2020/07/21 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly…
Aptose Announces Proposed Public Offering of Common Shares 2020/07/15 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced…
Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp? 2020/06/29 13:31:00 PR Newswire
NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Aptose to launch early-stage CG-806 study in acute myeloid leukemia (NASDAQ:APTO) 2020/06/29 11:38:37 Seeking Alpha
Aptose Biosciences (NASDAQ:APTO) is up 7% premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase
Aptose Biosciences : 2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas | MarketScreener 2020/06/22 15:12:05 MarketScreener
CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas … | June 22, 2020
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020 2020/07/21 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly…
Aptose Announces Proposed Public Offering of Common Shares 2020/07/15 20:01:00 GlobeNewswire
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced…
Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp? 2020/06/29 13:31:00 PR Newswire
NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Aptose to launch early-stage CG-806 study in acute myeloid leukemia (NASDAQ:APTO) 2020/06/29 11:38:37 Seeking Alpha
Aptose Biosciences (NASDAQ:APTO) is up 7% premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase
Aptose Biosciences : 2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas | MarketScreener 2020/06/22 15:12:05 MarketScreener
CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas … | June 22, 2020